Table 4.
Allograft outcomes in patients who initiated XOR inhibitor treatment prior to kidney transplantation compared with those who did not receive such treatment until posttransplant, or not at all.
| No XORi therapy pretransplant | XORi therapy pretransplant | p-value | |
|---|---|---|---|
| Number of patients | 8 | 10 | |
| Number of grafts | 11 | 11 | |
| Age at transplant, years | 42.8 (14.9–67.0) | 45.5 (20.7–66.2) | 0.974 |
| Delayed graft function | 2 | 3 | 1.0 |
| Posttransplant acute kidney injury | 7 | 4 | 0.395 |
| eGFR, mL/min/1.73 m2 | |||
| At 6 months | 24.9 (9.6–53.3) [9 grafts] | 61.5 (22.5–93) [10 grafts] | 0.003 |
| At 12 months | 27.5 (10.0–67.5) [9 grafts] | 64.8 (28–93.8) [10 grafts] | 0.035 |
| At 2 years | 16.2 (10.0–39.0) [6 grafts] | 61.3 (24.0–90.0) [8 grafts] | 0.009 |
| Biopsy-proven recurrence of DHA nephropathy | 10 | 3 | 0.004 |
| Graft loss due to recurrence of DHA nephropathy | 4 | 1 | 0.31 |
| Death | 5 | 1 | 0.043 |
| Death with a functioning graft | 3 | 1 | 0.275 |
Data are presented as median (range).
Abbreviations: eGFR, estimated glomerular filtration rate; DHA, 2,8-dihydroxyadenine; XORi, xanthine oxidoreductase inhibitor; AKI, acute kidney injury.